Macclesfield, United Kingdom
Monument Therapeutics, founded in 2019, is a forward-thinking biotechnology spin-out from Cambridge Cognition headquartered in the United Kingdom. The company positions itself at the intersection of health care and pharmaceutical industries with the goal of transforming neuroscience drug development through its slogan: "Bringing Precision Medicine to Neuroscience Drug Development".
Focused on addressing high unmet needs within the central nervous system, Monument Tx leverages proprietary digital biomarkers to minimize patient heterogeneity, thereby enhancing drug development efficacy. This precision medicine model emulates successful methodologies used in cancer treatment by identifying specific disease sub-types more likely to benefit from targeted compounds.
The company's latest financial milestone involved a £1.00M Venture Round investment on 18 April 2024, backed by noteworthy investor groups including Cambridge Angels group, SyndicateRoom, and Manchester Angels.
Alto Neuroscience